Evotec SE Ownership
| EVO Stock | USD 4.89 0.40 8.91% |
Shares in Circulation | First Issued 2003-03-31 | Previous Quarter 177.3 M | Current Value 177.3 M | Avarage Shares Outstanding 196.9 M | Quarterly Volatility 115.8 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Evotec |
Evotec Stock Ownership Analysis
The company has price-to-book (P/B) ratio of 1.57. Some equities with similar Price to Book (P/B) outperform the market in the long run. Evotec SE ADR has Price/Earnings (P/E) ratio of 444.0. The entity recorded a loss per share of 0.52. The firm last dividend was issued on the 12th of December 2018. Evotec SE had 4:1 split on the 20th of October 2021. Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany. Evotec Se operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 4715 people. To learn more about Evotec SE ADR call Mario DPHIL at 49 40 560 81 0 or check out https://www.evotec.com.Besides selling stocks to institutional investors, Evotec SE also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Evotec SE's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Evotec SE's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Evotec SE Quarterly Liabilities And Stockholders Equity |
|
Evotec Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Evotec SE is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Evotec SE ADR backward and forwards among themselves. Evotec SE's institutional investor refers to the entity that pools money to purchase Evotec SE's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Mariner Wealth Advisors Llc | 2024-06-30 | 12.3 K | Quadrant Capital Group Llc | 2024-09-30 | 6.2 K | Bank Of America Corp | 2024-06-30 | 6 K | Signaturefd, Llc | 2024-09-30 | 5.2 K | Briaud Financial Planning Inc | 2024-09-30 | 2.2 K | U.s. Bancorp | 2024-06-30 | 1.7 K | Parallel Advisors, Llc | 2024-06-30 | 1.5 K | Ubs Group Ag | 2024-06-30 | 1 K | Lindbrook Capital, Llc | 2024-09-30 | 712 | Novo A/s | 14.8 M | Mubadala Investment Company Pjsc | 2024-06-30 | 4.6 M |
Evotec SE ADR Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Evotec SE insiders, such as employees or executives, is commonly permitted as long as it does not rely on Evotec SE's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Evotec SE insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Zientek Michael over three months ago Acquisition by Zientek Michael of 200000 shares of Evotec SE at 2.5 subject to Rule 16b-3 | ||
Zientek Michael over three months ago Disposition of tradable shares by Zientek Michael of Evotec SE subject to Rule 16b-3 | ||
Anderson Mark Monroe over six months ago Acquisition by Anderson Mark Monroe of 100000 shares of Evotec SE at 2.5 subject to Rule 16b-3 |
Evotec SE Outstanding Bonds
Evotec SE issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Evotec SE ADR uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Evotec bonds can be classified according to their maturity, which is the date when Evotec SE ADR has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Evotec SE Corporate Filings
6K | 22nd of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
F3 | 8th of November 2024 The schedule filed by any person or group who acquires beneficial ownership of more than 5% of a voting class of a company's equity securities registered under Section 12 of the Act | ViewVerify |
| 14th of August 2024 Other Reports | ViewVerify | |
| 30th of April 2024 Other Reports | ViewVerify |
Pair Trading with Evotec SE
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evotec SE position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evotec SE will appreciate offsetting losses from the drop in the long position's value.Moving against Evotec Stock
| 0.9 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.84 | TCHH | Trustcash Holdings | PairCorr |
| 0.77 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.75 | AGL | agilon health Buyout Trend | PairCorr |
| 0.74 | ME | 23Andme Holding | PairCorr |
The ability to find closely correlated positions to Evotec SE could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evotec SE when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evotec SE - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evotec SE ADR to buy it.
The correlation of Evotec SE is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evotec SE moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evotec SE ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evotec SE can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evotec SE ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evotec SE. If investors know Evotec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evotec SE listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.52) | Revenue Per Share 2.1925 | Quarterly Revenue Growth (0.06) | Return On Assets (0.02) | Return On Equity (0.16) |
The market value of Evotec SE ADR is measured differently than its book value, which is the value of Evotec that is recorded on the company's balance sheet. Investors also form their own opinion of Evotec SE's value that differs from its market value or its book value, called intrinsic value, which is Evotec SE's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evotec SE's market value can be influenced by many factors that don't directly affect Evotec SE's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evotec SE's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evotec SE is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evotec SE's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.